Millions of customers have explored their genome with 23andMe. But when the company started in 2006, the idea of consumer DNA testing was heresy to the medical establishment. The FDA once even ordered 23andMe to stop selling its health testing product. The company persevered to make allies out of adversaries, and became the only FDA-approved product on the market. Learn how 23andMe defined the DNA testing category, and used its success to enter the massive new field of drug discovery.   
Host: Roelof Botha, Sequoia Capital  
Featuring: Anne Wojcicki, Richard Scheller  
Transcript: https://www.sequoiacap.com/podcast/crucible-moments-23andMe/
Learn more about your ad choices. Visit podcastchoices.com/adchoices

Roelof Botha

23andMe ft. Anne Wojcicki - How a DNA startup took on the FDA and redefined health tech

Millions of customers have explored their genome with 23andMe. But when the company started in 2006, the idea of consumer DNA testing was heresy to the medical establishment. The FDA once even ordered 23andMe to stop selling its health testing product. The company persevered to make allies out of adversaries, and became the only FDA-approved [&hellip;]